I wonder if Merck might want to enter a bidding war for Abivertinib?
Their anti-viral has been disappointing as one poster pointed out...
"The very close and divided 13-10 FDA panel vote for MRK's covid pill gives me great optimism given that MRK's covid pill only had a modest 30% efficacy rate and a questionable safety profile. Reminds me of Aduhelm's weak and questionable approval and you know how that turned out for BIIB."
This is a very good point and Abivertinib, COVI-MSC, COVI-AMG and COVIDROPS should interest them greatly! As a partner their influence with the FDA and marketing muscle would be very helpful.
Abivertinib's $61 Billion market in Covid,Cancer and Auto-immune indications will interest many Big Pharmas . And Merck will be one of them IMO!